300255 常山药业
已收盘 11-20 15:00:00
资讯
新帖
简况
11月20日常山药业跌6.45%,创业板医药ETF国泰基金重仓该股
证券之星 · 17:31
11月20日常山药业跌6.45%,创业板医药ETF国泰基金重仓该股
常山药业(300255)股东高树华质押1800万股,占总股本1.96%
证券之星 · 11-14
常山药业(300255)股东高树华质押1800万股,占总股本1.96%
股市必读:常山药业新发布《关于控股股东部分股份解除质押的公告》
证券之星 · 11-13
股市必读:常山药业新发布《关于控股股东部分股份解除质押的公告》
常山药业(300255)披露部分高级管理人员辞职公告,11月11日股价下跌1.04%
证券之星 · 11-11
常山药业(300255)披露部分高级管理人员辞职公告,11月11日股价下跌1.04%
常山药业(300255.SZ):肝素钠注射液获得玻利维亚药品注册证书
智通财经 · 11-10
常山药业(300255.SZ):肝素钠注射液获得玻利维亚药品注册证书
股市必读:常山药业新发布《关于控股股东部分股份解除质押的公告》
证券之星 · 11-06
股市必读:常山药业新发布《关于控股股东部分股份解除质押的公告》
常山药业(300255)披露控股股东部分股份解除质押公告,11月04日股价上涨4.12%
证券之星 · 11-04
常山药业(300255)披露控股股东部分股份解除质押公告,11月04日股价上涨4.12%
常山药业(300255)10月30日股东户数5.97万户,较上期减少1.38%
证券之星 · 11-02
常山药业(300255)10月30日股东户数5.97万户,较上期减少1.38%
常山药业:公司目前没有白蛋白耦合双靶点GLP-1及白蛋白耦合三靶点GLP-1专利
证券之星 · 11-02
常山药业:公司目前没有白蛋白耦合双靶点GLP-1及白蛋白耦合三靶点GLP-1专利
常山药业:截至2026年10月30日,公司的股东户数为59706户
证券之星 · 11-02
常山药业:截至2026年10月30日,公司的股东户数为59706户
常山药业(300255)2026年三季报简析:营收上升亏损收窄,盈利能力上升
证券之星 · 10-31
常山药业(300255)2026年三季报简析:营收上升亏损收窄,盈利能力上升
常山药业(300255)10月20日股东户数6.05万户,较上期增加0.97%
证券之星 · 10-29
常山药业(300255)10月20日股东户数6.05万户,较上期增加0.97%
图解常山药业三季报:第三季度单季净利润同比下降34.36%
证券之星 · 10-29
图解常山药业三季报:第三季度单季净利润同比下降34.36%
常山药业(300255.SZ)发布前三季度业绩,归母净亏损3789.44万元
智通财经 · 10-29
常山药业(300255.SZ)发布前三季度业绩,归母净亏损3789.44万元
常山药业:公司已按要求提交补充资料
证券之星 · 10-21
常山药业:公司已按要求提交补充资料
常山药业:截至2026年10月20日,公司的股东户数为60539户
证券之星 · 10-21
常山药业:截至2026年10月20日,公司的股东户数为60539户
常山药业:公司目前没有GLP-1双靶点及三靶点管线
证券之星 · 10-21
常山药业:公司目前没有GLP-1双靶点及三靶点管线
常山药业(300255)10月19日主力资金净卖出8213.31万元
证券之星 · 10-20
常山药业(300255)10月19日主力资金净卖出8213.31万元
常山药业最新公告:依诺肝素钠注射液通过欧盟DCP程序审评
证券之星 · 10-19
常山药业最新公告:依诺肝素钠注射液通过欧盟DCP程序审评
股市必读:常山药业新发布《关于依诺肝素钠注射液获得蒙古国药品注册证书的公告》
证券之星 · 10-19
股市必读:常山药业新发布《关于依诺肝素钠注射液获得蒙古国药品注册证书的公告》
加载更多
公司概况
公司名称:
河北常山生化药业股份有限公司
所属行业:
医药制造业
上市日期:
2011-08-19
主营业务:
河北常山生化药业股份有限公司的主营业务是肝素系列产品的研发、生产和销售。公司的主要产品是肝素钠、肝素钙、低分子量肝素钠(依诺肝素钠、达肝素钠)、低分子量肝素钙(那屈肝素钙)、透明质酸钠、枸橼酸西地那非、肝素钠注射液、低分子量肝素钙注射液、那屈肝素钙注射液、依诺肝素钠注射液、达肝素钠注射液。公司被认定为国家企业技术中心、中国创业创新典型示范企业、河北省A级研发中心、国家级高新技术企业、国家地方工程实验室、河北省多糖类药物工程技术研究中心、河北省出口名牌等。
发行价格:
28.00
{"stockData":{"symbol":"300255","market":"SZ","secType":"STK","nameCN":"常山药业","latestPrice":15.81,"timestamp":1795158186000,"preClose":16.9,"halted":0,"volume":17249392,"delay":0,"changeRate":-0.0645,"floatShares":918000000,"shares":919000000,"eps":-0.3819,"marketStatus":"已收盘","change":-1.09,"latestTime":"11-20 15:00:00","open":16.7,"high":16.74,"low":15.78,"amount":279000000,"amplitude":0.0568,"askPrice":15.82,"askSize":687,"bidPrice":15.81,"bidSize":22,"shortable":0,"etf":0,"ttmEps":-0.3819,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1795397400000},"marketStatusCode":5,"adr":0,"adjPreClose":16.9,"symbolType":"stock","openAndCloseTimeList":[[1795138200000,1795145400000],[1795150800000,1795158000000]],"highLimit":18.59,"lowLimit":15.21,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":919060878,"isCdr":false,"pbRate":13.31,"roa":"--","roe":"--","epsLYR":-0.39,"committee":-0.371755,"marketValue":14530000000,"turnoverRate":0.0188,"status":1,"floatMarketCap":14509000000},"requestUrl":"/m/hq/s/300255","defaultTab":"news","newsList":[{"id":"2684130738","title":"11月20日常山药业跌6.45%,创业板医药ETF国泰基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2684130738","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2684130738?lang=zh_cn&edition=full","pubTime":"2026-11-20 17:31","pubTimestamp":1795167091,"startTime":"0","endTime":"0","summary":"证券之星消息,11月20日常山药业跌6.45%创60日新低,收盘报15.81元,换手率1.88%,成交量17.25万手,成交额2.79亿元。重仓常山药业的公募基金请见下表:根据2026基金Q3季报公募基金重仓股数据,重仓该股的公募基金共1家,其中持有数量最多的公募基金为国泰基金的创业板医药ETF国泰。创业板医药ETF国泰的前十大重仓股如下:以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026112000030277.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0070","300255","BK0239","BK0172"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2683598507","title":"常山药业(300255)股东高树华质押1800万股,占总股本1.96%","url":"https://stock-news.laohu8.com/highlight/detail?id=2683598507","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2683598507?lang=zh_cn&edition=full","pubTime":"2026-11-14 00:20","pubTimestamp":1794586851,"startTime":"0","endTime":"0","summary":"证券之星消息,常山药业11月14日公开信息显示,股东高树华向**银行股份有限公司石家庄分行合计质押1800.0万股,占总股本1.96%。质押详情见下表:截止本公告日,股东高树华已累计质押股份1.84亿股,占其持股总数的65.72%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026111400000916.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0172","BK0070","300255","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2683516575","title":"股市必读:常山药业新发布《关于控股股东部分股份解除质押的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2683516575","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2683516575?lang=zh_cn&edition=full","pubTime":"2026-11-13 01:05","pubTimestamp":1794503117,"startTime":"0","endTime":"0","summary":"公司公告汇总关于控股股东部分股份解除质押的公告河北常山生化药业股份有限公司于2026年11月11日发布公告,公司控股股东高树华所持7,000,000股股份于2026年11月10日解除质押,占其所持股份2.49%,占公司总股本0.76%。本次解除质押起始日为2026年7月14日,质权人为***典当有限公司。截至公告披露日,高树华累计质押股份数量为166,433,700股,占其所持股份59.30%,占公司总股本18.11%;其持股总数为280,644,728股,持股比例30.54%。公司称其质押风险总体可控,不存在平仓风险。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026111300001707.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0172","BK0070","300255","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2682300596","title":"常山药业(300255)披露部分高级管理人员辞职公告,11月11日股价下跌1.04%","url":"https://stock-news.laohu8.com/highlight/detail?id=2682300596","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2682300596?lang=zh_cn&edition=full","pubTime":"2026-11-11 22:07","pubTimestamp":1794406037,"startTime":"0","endTime":"0","summary":"截至2026年11月11日收盘,常山药业报收于19.95元,较前一交易日下跌1.04%,最新总市值为183.35亿元。该股当日开盘20.08元,最高20.09元,最低19.44元,成交额达3.29亿元,换手率为1.81%。近日,河北常山生化药业股份有限公司披露《关于公司部分高级管理人员辞职的公告》。上述辞职申请自送达董事会之日起生效。截至公告披露日,二人均未持有公司股票,不存在应当履行而未履行的承诺事项,已做好工作交接,辞职不影响公司正常生产经营。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026111100046015.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300255","BK0239","BK0070","BK0172"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2682673263","title":"常山药业(300255.SZ):肝素钠注射液获得玻利维亚药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2682673263","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2682673263?lang=zh_cn&edition=full","pubTime":"2026-11-10 16:39","pubTimestamp":1794299988,"startTime":"0","endTime":"0","summary":"智通财经APP讯,常山药业(300255.SZ)发布公告,公司于近日收到通知,公司药品肝素钠注射液获得玻利维亚药品监督管理部门签发的药品注册证书,药品名称:“肝素钠注射液”。本次肝素钠注射液获得玻利维亚注册批文,对公司拓展海外市场带来一定积极影响。目前公司肝素制剂产品海外销售收入占公司营业总收入比例较低。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1521046.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0172","BK0239","BK0070","300255"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681003311","title":"股市必读:常山药业新发布《关于控股股东部分股份解除质押的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2681003311","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2681003311?lang=zh_cn&edition=full","pubTime":"2026-11-06 00:59","pubTimestamp":1793897952,"startTime":"0","endTime":"0","summary":"公司公告汇总:控股股东高树华于11月3日解除质押1977.27万股,占公司总股本2.15%。公司公告汇总关于控股股东部分股份解除质押的公告河北常山生化药业股份有限公司于2026年11月4日发布公告,公司控股股东高树华所持19,772,700股股份于2026年11月3日解除质押,占其所持股份7.05%,占公司总股本2.15%;质押起始日为2019年7月2日,质权人为华润深国投信托有限公司。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026110600001565.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300255","BK0239","BK0172","BK0070"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680057738","title":"常山药业(300255)披露控股股东部分股份解除质押公告,11月04日股价上涨4.12%","url":"https://stock-news.laohu8.com/highlight/detail?id=2680057738","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680057738?lang=zh_cn&edition=full","pubTime":"2026-11-04 22:17","pubTimestamp":1793801859,"startTime":"0","endTime":"0","summary":"截至2026年11月4日收盘,常山药业报收于19.98元,较前一交易日上涨4.12%,最新总市值为183.63亿元。近日,河北常山生化药业股份有限公司发布公告,公司控股股东高树华先生所持有的部分股份已于2026年11月3日解除质押。本次解除质押股份数量为19,772,700股,占其所持股份比例的7.05%,占公司总股本比例的2.15%,质押起始日为2019年7月2日,质权人为华润深国投信托有限公司。截至公告披露日,高树华累计质押股份173,433,700股,占其所持股份的61.80%,占公司总股本的18.87%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026110400043688.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0172","BK0239","BK0070","300255"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680075953","title":"常山药业(300255)10月30日股东户数5.97万户,较上期减少1.38%","url":"https://stock-news.laohu8.com/highlight/detail?id=2680075953","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680075953?lang=zh_cn&edition=full","pubTime":"2026-11-02 19:30","pubTimestamp":1793619058,"startTime":"0","endTime":"0","summary":"证券之星消息,近日常山药业披露,截至2026年10月30日公司股东户数为5.97万户,较10月20日减少833.0户,减幅为1.38%。在化学制药行业个股中,常山药业股东户数高于行业平均水平,截至10月30日,化学制药行业平均股东户数为3.98万户。从股价来看,2026年10月20日至2026年10月30日,常山药业区间跌幅为5.31%,在此期间股东户数减少833.0户,减幅为1.38%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026110200029458.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0070","BK0239","300255","BK0172"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680736170","title":"常山药业:公司目前没有白蛋白耦合双靶点GLP-1及白蛋白耦合三靶点GLP-1专利","url":"https://stock-news.laohu8.com/highlight/detail?id=2680736170","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680736170?lang=zh_cn&edition=full","pubTime":"2026-11-02 15:16","pubTimestamp":1793603762,"startTime":"0","endTime":"0","summary":"证券之星消息,常山药业(300255)11月02日在投资者关系平台上答复投资者关心的问题。投资者提问:尊敬的董秘,公司目前有没有白蛋白耦合双靶点glp-1及白蛋白耦合三靶点glp-1的专利?常山药业回复:尊敬的投资者,您好!公司目前没有白蛋白耦合双靶点GLP-1及白蛋白耦合三靶点GLP-1专利。感谢您的关注!本文数据来源于深圳证券交易所互动易,仅供参考不构成投资建议。责任编辑:陈思雨","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026110200017044.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300255","BK0239","BK0070","BK0172"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680101736","title":"常山药业:截至2026年10月30日,公司的股东户数为59706户","url":"https://stock-news.laohu8.com/highlight/detail?id=2680101736","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680101736?lang=zh_cn&edition=full","pubTime":"2026-11-02 15:15","pubTimestamp":1793603721,"startTime":"0","endTime":"0","summary":"证券之星消息,常山药业(300255)11月02日在投资者关系平台上答复投资者关心的问题。投资者提问:您好,请告知贵公司十月底的股东人数是多少,谢谢!常山药业回复:尊敬的投资者,您好!截至2026年10月30日,公司的股东户数为59706户。感谢您的关注!本文数据来源于深圳证券交易所互动易,仅供参考不构成投资建议。责任编辑:沈彬","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026110200017032.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0070","BK0239","300255","BK0172"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679222972","title":"常山药业(300255)2026年三季报简析:营收上升亏损收窄,盈利能力上升","url":"https://stock-news.laohu8.com/highlight/detail?id=2679222972","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2679222972?lang=zh_cn&edition=full","pubTime":"2026-10-31 11:51","pubTimestamp":1793418701,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理,近期常山药业发布2026年三季报。截至本报告期末,公司营业总收入7.36亿元,同比上升8.1%,归母净利润-3789.44万元,同比上升15.45%。本报告期常山药业盈利能力上升,毛利率同比增幅41.21%,净利率同比增幅25.08%。本次财报公布的各项数据指标表现尚佳。本文数据来源于常山药业2026年三季报,仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026103100025460.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300255"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679405326","title":"常山药业(300255)10月20日股东户数6.05万户,较上期增加0.97%","url":"https://stock-news.laohu8.com/highlight/detail?id=2679405326","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2679405326?lang=zh_cn&edition=full","pubTime":"2026-10-29 19:12","pubTimestamp":1793272323,"startTime":"0","endTime":"0","summary":"证券之星消息,近日常山药业披露,截至2026年10月20日公司股东户数为6.05万户,较10月9日增加582.0户,增幅为0.97%。在化学制药行业个股中,常山药业股东户数高于行业平均水平,截至10月20日,化学制药行业平均股东户数为3.95万户。从股价来看,2026年10月9日至2026年10月20日,常山药业区间跌幅为9.03%,在此期间股东户数增加582.0户,增幅为0.97%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102900046267.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300255","BK0239","BK0172","BK0070"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679477356","title":"图解常山药业三季报:第三季度单季净利润同比下降34.36%","url":"https://stock-news.laohu8.com/highlight/detail?id=2679477356","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2679477356?lang=zh_cn&edition=full","pubTime":"2026-10-29 18:33","pubTimestamp":1793270016,"startTime":"0","endTime":"0","summary":"证券之星消息,常山药业2026年三季报显示,前三季度公司主营收入7.36亿元,同比上升8.1%;归母净利润-3789.44万元,同比上升15.45%;扣非净利润-4260.15万元,同比上升10.66%;其中2026年第三季度,公司单季度主营收入2.61亿元,同比上升37.41%;单季度归母净利润-2113.26万元,同比下降34.36%;单季度扣非净利润-2074.04万元,同比下降19.01%;负债率73.88%,财务费用8303.89万元,毛利率22.47%。财报数据概要请见下图:本文数据来源于常山药业2026年三季报,仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102900043859.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300255"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679471612","title":"常山药业(300255.SZ)发布前三季度业绩,归母净亏损3789.44万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2679471612","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2679471612?lang=zh_cn&edition=full","pubTime":"2026-10-29 17:56","pubTimestamp":1793267815,"startTime":"0","endTime":"0","summary":"智通财经APP讯,常山药业(300255.SZ)发布2026年三季度报告,前三季度,公司实现营业收入7.36亿元,同比增长8.10%。归属于上市公司股东净亏损3789.44万元。归属于上市公司股东的扣除非经常性损益净亏损4260.15万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1515228.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["300255","BK0239","BK0070","BK0172"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677626874","title":"常山药业:公司已按要求提交补充资料","url":"https://stock-news.laohu8.com/highlight/detail?id=2677626874","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677626874?lang=zh_cn&edition=full","pubTime":"2026-10-21 15:51","pubTimestamp":1792569066,"startTime":"0","endTime":"0","summary":"证券之星消息,常山药业10月21日在投资者关系平台上答复投资者关心的问题。请问:1、本次提交的补充资料,CDE 是否已经完成签收核验,审评是否已经重新启动?公司已按要求提交补充资料。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102100023732.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0070","BK0172","BK0239","300255"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677626808","title":"常山药业:截至2026年10月20日,公司的股东户数为60539户","url":"https://stock-news.laohu8.com/highlight/detail?id=2677626808","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677626808?lang=zh_cn&edition=full","pubTime":"2026-10-21 15:48","pubTimestamp":1792568893,"startTime":"0","endTime":"0","summary":"证券之星消息,常山药业(300255)10月21日在投资者关系平台上答复投资者关心的问题。投资者提问:您好,请告知贵公司10月20日的股东人数是多少,谢谢!常山药业回复:尊敬的投资者,您好!截至2026年10月20日,公司的股东户数为60539户。感谢您的关注!本文数据来源于深圳证券交易所互动易,仅供参考不构成投资建议。责任编辑:陈思雨","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102100023396.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300255","BK0172","BK0070","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677462638","title":"常山药业:公司目前没有GLP-1双靶点及三靶点管线","url":"https://stock-news.laohu8.com/highlight/detail?id=2677462638","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677462638?lang=zh_cn&edition=full","pubTime":"2026-10-21 15:48","pubTimestamp":1792568889,"startTime":"0","endTime":"0","summary":"证券之星消息,常山药业(300255)10月21日在投资者关系平台上答复投资者关心的问题。投资者提问:尊敬的董秘,贵公司目前有没有glp-1双靶点及三靶点管线?常山药业回复:尊敬的投资者,您好!公司目前没有GLP-1双靶点及三靶点管线。感谢您的关注!本文数据来源于深圳证券交易所互动易,仅供参考不构成投资建议。责任编辑:陈思雨","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102100023383.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0172","BK0239","300255","BK0070"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2676630791","title":"常山药业(300255)10月19日主力资金净卖出8213.31万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2676630791","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2676630791?lang=zh_cn&edition=full","pubTime":"2026-10-20 09:18","pubTimestamp":1792459084,"startTime":"0","endTime":"0","summary":"证券之星消息,截至2026年10月19日收盘,常山药业报收于19.24元,下跌3.22%,换手率2.94%,成交量27.02万手,成交额5.14亿元。近5日资金流向一览见下表:常山药业融资融券信息显示,融资方面,当日融资买入2336.59万元,融资偿还7093.6万元,融资净偿还4757.02万元。常山药业主营业务:拥有完整肝素产品产业链、能够同时从事肝素粗品、肝素原料药和肝素制剂药品研发、生产和销售。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102000006472.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300255","BK0239","BK0172","BK0070"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2676250911","title":"常山药业最新公告:依诺肝素钠注射液通过欧盟DCP程序审评","url":"https://stock-news.laohu8.com/highlight/detail?id=2676250911","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2676250911?lang=zh_cn&edition=full","pubTime":"2026-10-19 16:36","pubTimestamp":1792399013,"startTime":"0","endTime":"0","summary":"常山药业(300255.SZ)公告称,公司近日收到欧盟克罗地亚药品及医疗器械管理局分散审批程序结束的通知,依诺肝素钠注射液已通过审评,结论为可批准。该药品用于预防静脉血栓栓塞性疾病、治疗深静脉栓塞等。本次通过审评是公司国际化注册的重要阶段性进展,若后续取得各成员国上市许可,将有利于拓展海外市场。目前公司肝素制剂产品海外销售收入占营收比例较低,预计不会对近期经营业绩产生重大影响。以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101900020617.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","FESXmain","300255","FSXEmain","BK0070","BK0172"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2676780305","title":"股市必读:常山药业新发布《关于依诺肝素钠注射液获得蒙古国药品注册证书的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2676780305","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2676780305?lang=zh_cn&edition=full","pubTime":"2026-10-19 02:22","pubTimestamp":1792347731,"startTime":"0","endTime":"0","summary":"截至2026年10月16日收盘,常山药业报收于19.88元,下跌2.02%,换手率2.29%,成交量21.02万手,成交额4.31亿元。公司公告汇总:常山药业依诺肝素钠注射液获蒙古国药品注册证书,注册号FR20260911BP09272,有效期至2031年9月11日。公司公告汇总关于依诺肝素钠注射液获得蒙古国药品注册证书的公告河北常山生化药业股份有限公司近日收到通知,其药品依诺肝素钠注射液获得蒙古国药品监督管理部门签发的药品注册证书,注册号为FR20260911BP09272,规格为60mg/0.6ml;N2,有效期至2031年9月11日。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101900000721.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0172","BK0070","300255","BK0239"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1795172992023,"stockEarnings":[{"period":"1week","weight":-0.1347},{"period":"1month","weight":-0.1613},{"period":"3month","weight":-0.311},{"period":"6month","weight":-0.5846},{"period":"1year","weight":-0.7077},{"period":"ytd","weight":-0.7279}],"compareEarnings":[{"period":"1week","weight":-0.0214},{"period":"1month","weight":-0.0422},{"period":"3month","weight":-0.0839},{"period":"6month","weight":-0.1301},{"period":"1year","weight":-0.0935},{"period":"ytd","weight":-0.0986}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"河北常山生化药业股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"58173人(较上一季度减少2.57%)","perCapita":"15775股","listingDate":"2011-08-19","address":"河北省石家庄市正定县中国(河北)自由贸易试验区正定片区高新技术产业开发区南区梦龙街71号","registeredCapital":"91906万元","survey":" 河北常山生化药业股份有限公司的主营业务是肝素系列产品的研发、生产和销售。公司的主要产品是肝素钠、肝素钙、低分子量肝素钠(依诺肝素钠、达肝素钠)、低分子量肝素钙(那屈肝素钙)、透明质酸钠、枸橼酸西地那非、肝素钠注射液、低分子量肝素钙注射液、那屈肝素钙注射液、依诺肝素钠注射液、达肝素钠注射液。公司被认定为国家企业技术中心、中国创业创新典型示范企业、河北省A级研发中心、国家级高新技术企业、国家地方工程实验室、河北省多糖类药物工程技术研究中心、河北省出口名牌等。","listedPrice":28},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.54.0","shortVersion":"4.54.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"常山药业(300255)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供常山药业(300255)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"常山药业,300255,常山药业股票,常山药业股票老虎,常山药业股票老虎国际,常山药业行情,常山药业股票行情,常山药业股价,常山药业股市,常山药业股票价格,常山药业股票交易,常山药业股票购买,常山药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"常山药业(300255)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供常山药业(300255)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}